Illumina (NASDAQ:ILMN) Given New $90.00 Price Target at Robert W. Baird

Illumina (NASDAQ:ILMN) had its price target cut by Robert W. Baird from $127.00 to $90.00 in a report released on Wednesday,Benzinga reports. They currently have a neutral rating on the life sciences company’s stock.

ILMN has been the subject of several other research reports. Hsbc Global Res cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. HSBC cut shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target for the company. in a research note on Friday, February 28th. Piper Sandler boosted their price target on shares of Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Guggenheim cut their price target on shares of Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Finally, TD Cowen cut shares of Illumina from a “buy” rating to a “hold” rating and cut their price target for the stock from $177.00 to $140.00 in a research note on Friday, February 7th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Illumina has an average rating of “Moderate Buy” and an average target price of $149.25.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $85.69 on Wednesday. The company has a 50 day moving average of $120.36 and a 200 day moving average of $132.17. The stock has a market cap of $13.57 billion, a P/E ratio of -11.16, a P/E/G ratio of 1.60 and a beta of 1.17. Illumina has a 12 month low of $80.18 and a 12 month high of $156.66. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, sell-side analysts forecast that Illumina will post 4.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Illumina

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Golden State Wealth Management LLC bought a new stake in Illumina during the 4th quarter valued at $32,000. Versant Capital Management Inc raised its holdings in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after buying an additional 146 shares during the last quarter. Fourth Dimension Wealth LLC bought a new stake in Illumina during the 4th quarter valued at $40,000. Bank Julius Baer & Co. Ltd Zurich bought a new stake in Illumina during the 4th quarter valued at $45,000. Finally, Assetmark Inc. raised its holdings in Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after buying an additional 296 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.